261 related articles for article (PubMed ID: 23394379)
41. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab.
Zimmerman LA; Zalieckas JM; Shamberger RC; Bousvaros A
J Pediatr Surg; 2018 Jul; 53(7):1330-1333. PubMed ID: 29370898
[TBL] [Abstract][Full Text] [Related]
42. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
43. Vedolizumab for the treatment of Crohn's disease.
Argollo M; Fiorino G; Peyrin-Biroulet L; Danese S
Expert Rev Clin Immunol; 2018 Mar; 14(3):179-189. PubMed ID: 29406811
[TBL] [Abstract][Full Text] [Related]
44. Crohn's disease with anorectal stenosis successfully treated with vedolizumab.
Urlep D; Orel R
World J Pediatr; 2017 Aug; 13(4):394-395. PubMed ID: 28540693
[No Abstract] [Full Text] [Related]
45. Molecular imaging of mucosal α4β7 integrin expression with the fluorescent anti-adhesion antibody vedolizumab in Crohn's disease.
Rath T; Bojarski C; Neurath MF; Atreya R
Gastrointest Endosc; 2017 Aug; 86(2):406-408. PubMed ID: 28137597
[No Abstract] [Full Text] [Related]
46. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.
Rosario M; Dirks NL; Milch C; Parikh A; Bargfrede M; Wyant T; Fedyk E; Fox I
Clin Pharmacokinet; 2017 Nov; 56(11):1287-1301. PubMed ID: 28523450
[TBL] [Abstract][Full Text] [Related]
47. Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.
Hirten R; Longman RS; Bosworth BP; Steinlauf A; Scherl E
Am J Gastroenterol; 2015 Dec; 110(12):1737-8. PubMed ID: 26673509
[No Abstract] [Full Text] [Related]
48. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2.
Feagan BG; Schwartz D; Danese S; Rubin DT; Lissoos TW; Xu J; Lasch K
J Crohns Colitis; 2018 Apr; 12(5):621-626. PubMed ID: 29471381
[TBL] [Abstract][Full Text] [Related]
50. New biologic therapeutics for ulcerative colitis and Crohn's disease.
Mozaffari S; Nikfar S; Abdolghaffari AH; Abdollahi M
Expert Opin Biol Ther; 2014 May; 14(5):583-600. PubMed ID: 24502344
[TBL] [Abstract][Full Text] [Related]
51. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
52. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.
Mahadevan U; Vermeire S; Lasch K; Abhyankar B; Bhayat F; Blake A; Dubinsky M
Aliment Pharmacol Ther; 2017 Apr; 45(7):941-950. PubMed ID: 28169436
[TBL] [Abstract][Full Text] [Related]
53. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
Wyant T; Fedyk E; Abhyankar B
J Crohns Colitis; 2016 Dec; 10(12):1437-1444. PubMed ID: 27252400
[TBL] [Abstract][Full Text] [Related]
54. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
Tsai HH; Black C
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457
[TBL] [Abstract][Full Text] [Related]
55. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
Riis A; Martinsen TC; Waldum HL; Fossmark R
Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
[TBL] [Abstract][Full Text] [Related]
56. Anti-tumour necrosis factor-alpha therapies in Crohn's disease.
Sprakes MB; Hamlin PJ
Br J Hosp Med (Lond); 2009 Nov; 70(11):644-7. PubMed ID: 20081592
[TBL] [Abstract][Full Text] [Related]
57. Combination therapy for the treatment of Crohn's disease.
Mosli MH; Feagan BG
Expert Opin Biol Ther; 2015; 15(10):1429-42. PubMed ID: 26211474
[TBL] [Abstract][Full Text] [Related]
58. Sweet syndrome after treatment with vedolizumab in a patient with Crohn's disease.
Martínez Andrés B; Sastre Lozano V; Sánchez Melgarejo JF
Rev Esp Enferm Dig; 2018 Aug; 110(8):530. PubMed ID: 29900741
[TBL] [Abstract][Full Text] [Related]
59. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs.
Krygier DS; Ko HH; Bressler B
Expert Rev Gastroenterol Hepatol; 2009 Aug; 3(4):407-15. PubMed ID: 19673627
[TBL] [Abstract][Full Text] [Related]
60. Nodular Vasculitis in a Patient With Crohn's Disease on Vedolizumab.
Pouldar D; Elsensohn A; Ortenzio F; Shiu J; McLeod M; de Feraudy S
Am J Dermatopathol; 2018 Mar; 40(3):e36-e37. PubMed ID: 28953016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
